Free-text search
Content Types
-
Sanofi strikes another multibillion-dollar deal – four candidates in focus
Sanofi and Regeneron are stepping up their long-standing partnership. The companies are now investing in four new antibody drugs in a deal that could be worth up to $8 billion.
-
New AI model could reduce unnecessary surgery for women
Every misjudged ovarian abnormality costs time, money and unnecessary anxiety. A new AI model may offer a solution – once it is fully implemented into the patient pathway.
-
TLV on Kisunla: High cost, high uncertainty
High treatment costs and considerable uncertainty regarding the durability of the treatment effect. That is TLV’s overall verdict on Eli Lilly’s Alzheimer therapy Kisunla.
-
Invisible hearing implant launched – entire device sits beneath the skin
A cochlear implant in which all components, including the microphone, are implanted beneath the skin is now being launched across Europe. According to Ingeborg ...
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.
-
Ulf Landegren: From scientific discovery to successful companies
He is a scientist, inventor and entrepreneur with a string of successful companies to his name. Now, Ulf Landegren, a professor at Uppsala University, is to rec...
-
Medivir’s second act: three drugs to enter Phase 2
As recently as last autumn, the situation was critical, with cash reserves dwindling and the share price falling. Today, Medivir is well funded, its ownership s...
-
Sprint Bioscience builds the molecules that will become new medicines
In Sprint Bioscience’s laboratory in Flemingsberg, Huddinge, molecules are being created that no one has ever built before. The company specializes in preclinic...
-
Saniona moves depression drug closer to first-in-human trial
The Swedish-Danish research company Saniona has submitted an application to the FDA to begin testing its oral drug candidate in patients with major depressive disorder.
-
GSK to cut 1,200 jobs in Belgium
More than 1,200 jobs at UK pharma giant GSK are at risk in Belgium as part of a major cost-cutting drive.
-
Integrated Clinical and Regulatory Support for Oncology Trials
Aurevia is a European Contract Research Organization (CRO) and regulatory partner supporting biotech, pharmaceutical, and medtech companies in the development a...
-
We are expanding our English-language coverage
Over a period of four weeks, one of Life Science Sweden's regular daily newsletters is being published entirely in English. The aim is to meet increasing demand...
-
Samuel Lagercrantz: ”Hansa och Bioarctic visar styrka – men klarar de nästa steg?”
, kan ta sig vidare och bli mer än one hit wonders.
-
Anna Törner: Time for new body ideals?
Why are perfectly healthy people turning to high-tech medicines to achieve outdated beauty ideals? Anna Törner asks in her latest column.
-
Ambu expands their bronchoscopy offering
Ambu's bronchoscope offering has been cleared for use in the pediatric segment.
-
AstraZeneca opens $1bn R&D centre in US
AstraZeneca has now opened its new research and development centre in Cambridge, Massachusetts – an investment of nearly 1 billion dollars.
-
Modus shares halve after safety-related trial pause
Swedish biotech Modus Therapeutics has temporarily paused recruitment to its Phase IIa trial in anaemia associated with chronic kidney disease following a serio...
-
Xbrane reaches milestone with biosimilar to blockbuster cancer drug
Swedish biotech Xbrane is taking another step in developing a biosimilar to Bristol Myers Squibb’s blockbuster cancer drug Opdivo. All patients have now been en...
-
Oncopeptides raises SEK 100 million after brain cancer breakthrough
Swedish biotech Oncopeptides is raising SEK 100 million through a directed share issue. The announcement comes days after the company reported progress with its...
-
Bristol Myers Squibb reports dual Phase III success
Bristol Myers Squibb has reported positive late-stage results for drug candidates targeting idiopathic pulmonary fibrosis and neuroendocrine tumours of the gast...
-
Roche's Tecentriq gets FDA nod after strong colon cancer data
A combination of Tecentriq and chemotherapy cut the risk of recurrence or death by half in patients with stage III colon cancer and dMMR tumours. The results ha...
-
Forbion raises €2.3bn in record life science fundraising
Dutch life science investor Forbion has raised 2.3 billion euros – capital that could provide funding for around 30 biotech companies.
-
Gene therapies on clinical hold after tumour found in five‑year‑old
The development of a brain tumour in a study participant has led the FDA to temporarily halt two ongoing gene therapy programs. The affected company, Regenxbio,...
-
Hansa chair: “Too many boards spend far too much time looking inwards”
Following a change of chief executive and a sharper strategic focus, Hansa Biopharma is entering a decisive phase in the US market. As the company prepares for ...
BREAKING